article thumbnail

Xolair amplifies reach after FDA approval for treating food allergies 

Pharmaceutical Technology

Xolair is the first FDA-approved drug to reduce allergic reactions in people with one or more food allergies, as per Roche’s announcement.

Allergies 236
article thumbnail

FDA approves Ipsen’s Onivyde for pancreatic adenocarcinoma

Pharmaceutical Technology

Ipsen reported that the US FDA approved the Onivyde regimen (NALIRIFOX) as a first-line treatment for metastatic pancreatic cancer.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Iovance’s Amtagvi for melanoma treatment gains FDA approval

Pharmaceutical Technology

Iovance Biotherapeutics' Amtagvi has received accelerated US FDA approval for treating adults with metastatic or unresectable melanoma.

article thumbnail

Takeda’s EOHILIA receives FDA approval for EoE treatment

Pharmaceutical Technology

Takeda has received the US FDA approval for EOHILIA (budesonide oral suspension), an oral treatment for eosinophilic esophagitis (EoE).

article thumbnail

US FDA approves Bausch + Lomb and Novaliq’s DED treatment Miebo

Pharmaceutical Technology

It is the first and only prescription eye drop to receive FDA approval to treat DED that targets tear evaporation directly. Bausch + Lomb chairman and CEO Brent Saunders stated: “Today’s FDA approval of Miebo further advances DED treatment by addressing a significant unmet need for millions of people suffering with this disease.

article thumbnail

Rystiggo receives FDA approval, strengthening UCB’s myasthenia gravis portfolio

Pharmaceutical Technology

UCB's Rystiggo has been granted FDA approval to treat myasthenia gravis in anti-AchR or anti-MuSK antibody-positive adults.

article thumbnail

Roctavian and BioMarin’s $2.9m haemophilia gene therapy secures FDA approval

Pharmaceutical Technology

BioMarin’s Roctavian, a one-time therapy for severe haemophilia A, has secured FDA approval following previous rejections and delays.